MetaCap

Gossamer Bio (GOSS) vs vTv Therapeutics (VTVT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

vTv Therapeutics (VTVT) has outperformed Gossamer Bio (GOSS) over the past year, losing 47.5% versus a loss of 95.6%. Over five years, VTVT leads with a -71.1% price change compared with -98.7% for GOSS. Gossamer Bio is the larger company by market cap ($65.6 million vs $62.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GOSS-95.62%VTVT-47.53%
+52%-26%-104%
Nov 21, 20251 yearNov 20, 2026
GOSS-98.84%VTVT-72.69%
+30%-38%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GOSS versus VTVT key metrics
MetricGOSSVTVT
Share price$10.72$15.51
Market cap$65.57M$62.22M
1-day change-4.54%-5.20%
YTD return-95.68%-61.22%
1-year return-95.62%-47.53%
5-year return-98.74%-71.06%
EPS (TTM)$-42.41$-0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$48.47M$0
Revenue growth (YoY)-57.74%-100.00%
Net income (latest FY)$-170.37M$-26.97M
Operating margin-352.23%—
Net margin-351.49%—
52-week high$309.60$44.00
52-week low$8.29$15.47
Distance from 52-week high-96.54%-64.75%
Analyst consensusbuystrong_buy
Avg. price target upside+669.40%+261.06%
Average volume243.40K33.07K
Shares outstanding6.12M4.01M
Employees16126
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VTVT has outperformed GOSS by 48.1 percentage points over the past year.
  • Gossamer Bio grew revenue faster in its latest fiscal year (-57.74% vs -100.00%).

About Gossamer Bio

GOSS stock →

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

About vTv Therapeutics

VTVT stock →

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees

GOSS vs VTVT FAQ

Which is bigger, Gossamer Bio or vTv Therapeutics?

Gossamer Bio (GOSS) is larger, with a market capitalization of $65.57M compared with $62.22M for vTv Therapeutics (VTVT).

Which stock has performed better over the past year, GOSS or VTVT?

VTVT returned -47.53% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.

Are Gossamer Bio and vTv Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons